B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Staff Accountant

Full-Time
$77k - $100k
Mid
Bachelor's
Stamford, CT, USA
HybridAt least two days on-site per week, currently Tuesday and Wednesday.
AccountingFinancial Accounting

About the job

Requirements
  • A bachelor's degree in Accounting or Finance is required.
  • Three years of accounting experience in a corporate, public accounting, or life sciences environment.
  • Foundational knowledge of U.S. GAAP accounting principles, including accrual accounting, reconciliation preparation, journal entry documentation, and basic financial statement concepts.
  • Proficiency in Microsoft Excel, including preparing and maintaining accounting schedules, reconciliations, and supporting workpapers; experience with VLOOKUP, pivot tables, and basic financial formulas.
  • Familiarity with accounting software or ERP systems such as NetSuite, QuickBooks, or equivalent, and willingness to learn the organization's financial systems.
  • Strong attention to detail and organizational skills to manage multiple accounting tasks, consistently meet close deadlines, and maintain accurate financial records.
  • Ability to meet deadlines, follow through on assigned responsibilities, and communicate proactively when issues or questions arise.
  • A process-minded approach to improving work efficiency, documentation, and the quality of accounting close processes.
  • Clear, professional written and verbal communication with vendors, internal stakeholders, and Finance team members.
  • Ability to respond to requests from the Finance team, external auditors, and cross-functional partners in a timely and professional manner.
Responsibilities
  • Support the monthly financial close by preparing and posting journal entries, performing account reconciliations, and assisting with close workpapers for prepaid expenses, accruals, and fixed assets.
  • Process and manage accounts payable, including reviewing and coding vendor invoices, coordinating approval workflows, maintaining vendor records, and supporting timely and accurate payment processing according to company policies.
  • Prepare and maintain accounting schedules and supporting documentation for assigned balance sheet accounts, ensuring reconciliations are accurate, timely, and supported by appropriate documentation.
  • Support clinical and research program accruals by working with Clinical Operations, Finance, and external vendors to track program expenditures, estimate accruals, and accurately record CRO and research-related costs.
  • Assist with external audit support by organizing workpapers, preparing schedules, and gathering documentation in response to auditor requests under the direction of the Manager, Accounting.
  • Support accounts payable vendor management by maintaining vendor master data, processing new vendor setups, and ensuring W-9/W-8 compliance in coordination with Tax and Finance leadership.
  • Identify opportunities to streamline accounting workflows, improve documentation standards, and enhance the efficiency of close and reporting activities.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • CPA exam eligibility or active progress toward CPA licensure.
  • Experience with general ledger accounting, accounts payable, or financial close processes.
  • Life sciences or biotechnology experience.

About the company

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...